🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to researchers.

An International Challenge

Gonorrhoea infections are on the rise globally, with data suggesting more than 82 million new cases each year. Notably increased rates are reported in Africa and nations within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely advancement in the face of rising global incidence, increasing antimicrobial resistance and the highly restricted treatment choices presently on offer.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Clearance

Zoliflodacin, also known as a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, developed by the drugmaker GSK, gained clearance in close succession. This treatment, which is employed against urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP worked alongside the drug firm its industry partner to develop it.

“This milestone represents a significant shift in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Data and Global Access

According to data published in a major medical journal, zoliflodacin successfully treated more than 90% of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines a dual-drug approach. The research included over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals treating patients have expressed positive views. The availability of a easy-to-administer therapy like this is described as a "game-changer" for managing the epidemic. This is viewed as vital to lessen the impact of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea around the world.